Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sanofi/Regeneron Get Reprieve: Praluent Can Stay On Market For Now

Executive Summary

Federal Circuit stays injunction that would have halted sales of the PCSK9 inhibitor on Feb. 21; stay extends through appeal of injunction and patent verdict.

You may also be interested in...



Praluent Lives On As US Court Vacates Amgen's PCSK9 Patent Win

While sales of Sanofi/Regeneron's Praluent, which will remain on the US market for the time being, could see a small boost, larger commercial challenges in the PCSK9 category linger.

Praluent Injunction Goes Unmentioned At PCSK9 Patent Case Appeal

Three-judge US federal appellate panel focuses on evidentiary rulings and patent validity in the dispute between Repatha marketer Amgen and Sanofi/Regeneron; lower court’s permanent injunction barring sales of Praluent did not come up at oral arguments.

PCSK9 Sponsors Still Face Challenges In Turning Around Dismal Launches

After reporting yet another quarter of disappointing sales, Amgen and Sanofi/Regeneron look forward to better performance now that outcomes data are out, but payers may not be up for easing hurdles enough.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS120005

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel